Antibodies, Everyone?
Executive Summary
A cluster of recent deals indicates just how hot antibodies are right now, and also hints at some old difficulties and new opportunities in the field.You may also be interested in...
When is a Target Not a Target?
Medarex is reevaluating its plans to bring 10 antibodies into the clinic each year, in part because targets identified by its array of young partners are taking a lot of work to validate. The company has gained appreciation for vaccines and for the potential of using antibodies as general immune stimulants rather than specifically targeted therapeutics.
EPIcyte Pharmaceutical Inc.
EPIcyte has licensed patents from the Scripps Research Institute covering new methods of human antibody production in plants that can lower costs up to 100 fold. The company is also developing proprietary products based on its technology, initially, an anti-herpes prophylactic and a contraceptive based on an anti-sperm antibody.
USMCA Passes Muster In US Senate
The US Senate’s vote to approve legislation underpinning the US-Mexico-Canada trade agreement has been welcomed by the country’s off-patent industry.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports